文献速递物质与行为成瘾

NK1受体拮抗可防止阿片类药物滥用潜力

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.
PubMed 文献 · Mol Psychiatry · 2017-05-09

该研究靶向参与疼痛与成瘾的神经激肽系统,通过VTA区NK1R基因编辑使吗啡失去奖赏效应,并验证μ/δ阿片激动剂与NK1R拮抗剂双价药效团在急性疼痛动物模型中抑制痛觉且无正性强化。

要点

  • VTA区NK1R基因编辑使吗啡不再产生奖赏效应。
  • 双价μ/δ激动剂-NK1R拮抗剂抑制急性疼痛且无正性强化。
  • 双重靶向多巴胺奖赏环路与疼痛通路或可开发无滥用潜力镇痛药。

核心结论

  • 靶向NK1R的遗传或药理拮抗可阻止阿片类药物的滥用潜力。
  • 多功能阿片激动剂-NK1R拮抗剂可能成为无滥用潜力的未来镇痛药策略。

研究设计与样本

  • 动物模型研究:VTA区NK1R基因组编辑及双价药效团药理干预。
  • 急性疼痛动物模型评估痛觉抑制与正性强化。

主要发现

  • VTA区NK1R基因组编辑使吗啡失去奖赏效应。
  • 双价μ/δ阿片激动剂-NK1R拮抗剂在急性疼痛动物模型中抑制痛觉且无正性强化。
  • 吗啡至少部分通过抑制VTA区SP神经元上的GABA能输入增加SP释放至多巴胺神经元而发挥奖赏作用。

临床怎么用

  • 为开发无滥用潜力的镇痛药提供双重靶向多巴胺奖赏环路与疼痛通路的策略思路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Development of an efficacious, non-addicting analgesic has been challenging. Discovery of novel mechanisms underlying addiction may present a solution. Here we target the neurokinin system, which is involved in both pain and addiction. Morphine exerts its rewarding actions, at least in part, by inhibiting GABAergic input onto substance P (SP) neurons in the ventral tegmental area (VTA), subsequently increasing SP release onto dopaminergic neurons. Genome editing of the neurokinin 1 receptor (NK1R) in the VTA renders morphine non-rewarding. Complementing our genetic approach, we demonstrate utility of a bivalent pharmacophore with dual activity as a μ/δ opioid agonist and NK1R antagonist in inhibiting nociception in an animal model of acute pain while lacking any positive reinforcement. These data indicate that dual targeting of the dopaminergic reward circuitry and pain pathways with a multifunctional opioid agonist-NK1R antagonist may be an efficacious strategy in developing future analgesics that lack abuse potential.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Sandweiss AJ, McIntosh MI, Moutal A, et al. Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential. Mol Psychiatry. 2017. PMID: 28485408. doi:10.1038/mp.2017.102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。